KRYS vs QGEN: stock comparison and AI forecast
Krystal Biotech, Inc. (KRYS) and Qiagen N.V. (QGEN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KRYS Krystal Biotech, Inc.
- Price
- $295.90 +3.1% · 6M
- Market Cap
- $9.04B
- P/E Ratio
- 41.5x
- Size
- mid-cap
- AI Forecast
QGEN Qiagen N.V.
- Price
- $50.35 +48.3% · 6M
- Market Cap
- $10.93B
- P/E Ratio
- 35.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- QGEN is 1.2 times larger than KRYS by market capitalization ($10.93B against $9.04B).
- QGEN trades at 35.7 times trailing earnings, KRYS at 41.5 times.
- Over the last six months QGEN returned +48.3% and KRYS +3.1%.
- KRYS turns 47.9% of its revenue into net income, against 15.6% for QGEN.
- QGEN carries 0.66 times debt per unit of equity, against 0.10 times for KRYS.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KRYS | QGEN |
|---|---|---|
| Market Cap | $9.04B | $10.93B |
| P/E Ratio | 41.45x | 35.73x |
| P/B Ratio | 6.30x | 2.89x |
| EPS | $7.36 | $1.41 |
| Book Value/Share | $48.44 | $17.42 |
| Revenue/Share | $15.86 | – |
| FCF/Share | $10.46 | – |
Profitability & Margins
| Metric | KRYS | QGEN |
|---|---|---|
| ROE | 15.7% | 8.4% |
| ROA | 14.2% | 5.1% |
| ROIC | 15.8% | 6.5% |
| Gross Margin | – | 59.8% |
| Operating Margin | 48.4% | 18.4% |
| Net Margin | 47.9% | 15.6% |
| EBT Margin | 55.1% | 19.0% |
| Tax Rate | 13.0% | 18.1% |
Financial Health
| Metric | KRYS | QGEN |
|---|---|---|
| Current Ratio | 7.89x | 3.90x |
| Quick Ratio | 7.53x | 3.31x |
| D/E Ratio | 0.10x | 0.66x |
| Financial Leverage | 1.10x | 1.66x |
| Interest Coverage | – | 15.9x |
| Working Capital | $980M | $1.48B |
Cash Flow
| Metric | KRYS | QGEN |
|---|---|---|
| Operating Cash Flow | $324M | $626M |
| Free Cash Flow | $310M | – |
| Capital Spending | -$14M | – |
| OCF Growth YoY | 83.8% | 40.0% |
| FCF Growth YoY | 87.3% | – |
| FCF/Sales | 66.0% | – |
| CapEx/Sales | 3.0% | – |
Operational Efficiency
| Metric | KRYS | QGEN |
|---|---|---|
| Asset Turnover | 0.30x | – |
| Receivables Turnover | 3.5x | – |
| Inventory Turnover | – | 2.7x |
| Fixed Assets Turnover | 3.1x | – |
| Days Sales Outstanding | 103 days | – |
| Days Inventory | – | 134 days |
| Payables Period | – | 32 days |
Income Statement
| Metric | KRYS | QGEN |
|---|---|---|
| Total Revenue | $470M | – |
| Operating Income | $228M | $376M |
| Net Income | $225M | $318M |
| R&D Expense | $60M | $192M |
| SG&A Expense | $156M | $678M |
| Cost of Goods Sold | – | $822M |
Dividend & Shareholder Information
| Metric | KRYS | QGEN |
|---|---|---|
| Shares Outstanding | 30M | 217M |
| Net Income Growth | 13.2% | – |
| EPS Growth | 1.7% | 28.5% |
KRYS vs QGEN: stock comparison and AI forecast
Which is bigger, KRYS or QGEN?
QGEN is 1.2 times larger than KRYS by market capitalization ($10.93B against $9.04B).
Which is cheaper on earnings, KRYS or QGEN?
QGEN trades at 35.7 times trailing earnings, KRYS at 41.5 times.
Which stock performed better over the last six months, KRYS or QGEN?
Over the last six months QGEN returned +48.3% and KRYS +3.1%.
Which one does Intratio's AI model rank higher, KRYS or QGEN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.